Day traders' weekend lounge May 6 - 8, page-35

Hi mirren

HIV: since the 2018 great spike, Biotron have been mostly trying to identify the mode of action of BIT225. Having great results - clearing macrophage reservoir cells- was a great achievement, but not knowing exactly how slowed further progress. That hurdle was overcome 2021 and three new trials commenced with more precise end points that will certainly put 225 in a better place for entry to phase 3. As you know, phase 3 never occurs unless all boxes are ticked. Australian trials with St Vincents and one in Thailand. Initial results not coming until later this year. It is worth mentioning that the research they've done in the last two years was published and now creates the backbone to further development ie phase 3. Naturally, it won't occur until the new trials are near complete, so next year.

Covid19.

yes, only animal trials to date, but that is about to change very soon when (if) entering CTAP. As far as drug developments go, like the covid vaccine development, its happening at lightning speed. These very successful mice trials have proven several things: non progression of C19 disease; and very importantly, non progression of disease when drug candidate given after disease onset. This is a first for all drugs being used to treat C19 (albeit in mice only so far).

The CTAP notice is imminent, and if successful, all I can say is that traders don't want to be caught not holding, at least not for long.......

Entering CTAP is only the first stage of this new era, and will cause a paradigm shift for Biotron (if) when it goes ahead. The results of CTAP of course is what will make or brake us as far as C19 goes. CTAP ha sonly approved one drug so far for treating C19, Paxlovid, by Pfizer. However, not all is rosy with this new wonder drug.
https://abcnews.go.com/Health/scientists-investigate-perplexing-viral-rebound-covid-19-cases/story?id=84475465

Considering BIT225's very high safety profile after nine HIV trials, and with its ability to clear latent HIV virus, any similar results with C19, as it has in the high ACE2 mice, will see it potentially even replacing Paxlovid.

Let's just settle for selling like Paxlovid.

That's the optimistic outcome. The lesser version sees all bats shot from skies.